The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

Per thor Straten and Mads Hald Andersen

* Center for Cancer Immune Therapy (CCIT), Department of Hematology, Herlev University Hospital, DK-2730 Herlev, Denmark

Correspondence to: Mads Hald Andersen, e-mail: mahaan01@heh.regionh.dk

Keywords: Bcl-2, Bcl-X(L), Mcl-1, cancer vaccines, immune therapy, tumor antigens

Received: July 2, 2010, Accepted: August 9, 2010, Published: August 10, 2010

Copyright: © 2010 thor Straten et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT:

Anti-apoptotic members of the Bcl-2 family (Bcl-2, Bcl-X(L) and Mcl-2) are pivotal regulators of apoptotic cell death. They are all highly overexpressed in cancers of different origin in which they enhance the survival of the cancer cells. Consequently, they represent prime candidates for anti-cancer therapy and specific antisense oligonucleotides or small molecule inhibitors have shown broad anti-cancer activities in pre-clinical models and are currently tested in clinical trials. In addition, immune-mediated tumor destruction is emerging as an interesting modality to treat cancer patients. Notably, spontaneous cellular immune responses against the Bcl-2 family proteins have been identified as frequent features in cancer patients underscoring that these proteins are natural targets for the immune system. Thus, Bcl-2 family may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies, alone or in the combination with conventional therapy. Here, we summarize the current knowledge of Bcl-2 family proteins as T-cell antigens, which has set the stage for the first explorative trial using these antigens in therapeutic vaccinations against cancer, and discuss future opportunities.

Abbreviations Used: AI apoptotic index; ALL acute lymphoid leukaemia; AML acute myeloid leukemia; B-CLL B-cell chronic lymphocytic leukemia; CTL cytotoxic T cells;

INTRODUCTION

The use of cancer vaccines to induce anti-tumor immune responses holds huge potential to complement traditional cancer therapies. Currently around 50 different therapeutic cancer vaccines have reached phase III clinical testing (not including HPV-based clinical trials) and the FDA has recently approved the first therapeutic cancer vaccine in the US (Dendreon’s Provenge, sipuleucel-T). Moreover, more than 400 phase I trials and more than 430 phase II trials are testing therapeutic cancer vaccines in the clinic (www.clinicaltrials.gov). Cancer vaccines are designed to re-calibrate the existing host-tumour interaction, tipping the balance from tumor acceptance towards tumor control to the benefit of the cancer patient.

Immunization evolves in a stepwise fashion beginning with an innate inflammatory response at the site of danger involving mast cells, resident and/or migrant monocytes, as well as NK cells and granulocytes [1]. Their effector function, e.g. secretion of pro-inflammatory chemo-/cytokines, innate cytotoxicity and thereby release of antigen, together with their capacity of antigen uptake and migratory phenotype are prerequisites to mount an adaptive immune response. Inflammatory signals allow their migration to loco-regional lymph nodes where they either transfer the antigen to professional APC or directly encounter cognate naïve or memory T cells which upon antigen recognition get activated. Primed T cells return to circulation as memory and/or effector T cells and patrol the organism in search of the relevant targets. While T-helper cells influence the activation of B- and antigen-presenting cells as well as cytotoxic T cells (CTL) only the latter have a vital function in monitoring the cells of the body and eliminating cells that are flagged for destruction and display the appropriate antigen. This function has been firmly established for virus-infected cells. However, in addition CTL are thought to provide some degree of protection against spontaneous tumors, by virtue of their
ability to detect quantitative and qualitative antigenic differences in transformed cells [2,3]. Tumorigenic alterations result in an altered protein repertoire inside the cell. Class I HLA molecules sample peptides from protein-degradation inside the cell and present these at the cell surface to CTL. Thus, it is well established that peptide epitopes derived from human tumor-associated antigens, can be recognized by CTL in the context of HLA molecules [4]. Spontaneous cancers represent approx. 80% of all cancers and obviously, the antigens potentially recognized by the immune system are basically “self” antigens. Nevertheless, it is now well documented that the immune system is in fact capable of recognizing spontaneous cancers. Thus, even in the absence of treatment, cells of the immune system in the cancer patients specifically recognize cancer cells. Moreover, CTL responsible for cancer cell recognition are capable of killing cancer cells and leaving normal cells unharmed. The molecular targets recognized – which derive from proteins present in the cancer cells - encompass structures that potentially are applicable in anti-cancer vaccination strategies. A large number of such target structures have been characterized over the past more than 10 years [5].

The phenomenon of “immune escape”, in which antigen-negative cancer cells avoid immune recognition, strategies have been developed that conceptually focus on specifically targeting proteins that are important for the function, survival and growth of cancer cells [6]. Likewise, the tumor microenvironment, and conventional disease management has been taken into consideration. In this regard, anti-apoptotic molecules that enhance the survival of cancer cells and facilitate their escape from cytotoxic therapies represent prime candidates for immunological intervention.

Most malignancies are characterized by defects in apoptotic signalling cascades, e.g. an overexpression of the inhibitor of apoptosis protein survivin or proteins from the Bcl-2 family (e.g. Bcl-2, Bcl-X(L), or Mcl-1). Numerous studies have demonstrated Bcl-2 over-expression in solid tumors, including melanoma, breast, colorectal, prostate, and small cell lung cancer as well as cancers of hematological origin [7-12]. Bcl-X(L) is likewise implicated in the pathogenesis of cancer and increased expression is a characteristic of acute myeloid leukemia (AML) and multiple myeloma, as well as solid cancers like bladder cancer, breast cancer, pancreatic cancer and melanoma [13]. While co-expression of Bcl-2 and Bcl-X(L) is seen in some cancers, others exhibit exclusive expression of one or the other protein. In contrast to our current understanding of Bcl-2 and Bcl-X(L), considerably less is known about the role of other anti-apoptotic Bcl-2 family members. However, elevated levels of Mcl-1 have been reported for a number of solid tumors and B-cell chronic lymphocytic leukemia (B-CLL) as well as as AML and acute lymphoid leukemia (ALL) upon relapse [13-16].

Attempts to overcome the cytoprotective effects of Bcl-2, Bcl-X(L) and Mcl-1 in cancer include several different strategies (as reviewed in [17]): (i) shutting off gene transcription, (ii) inducing mRNA degradation with antisense oligonucleotides [18], and (iii) directly attacking the proteins with small-molecule drugs [19-21]. A randomized clinical trial for metastatic melanoma comparing dacarbazine alone with dacarbazine and Bcl-2 antisense demonstrated an increase in response rates and improved survival in patients with less aggressive disease, but not in patients with more aggressive disease [22]. In addition to the above-mentioned means of targeting, immune-mediated tumor destruction is emerging as an interesting modality to treat cancer patients. Notably, during the last decade spontaneous cellular immune responses against regulators of apoptosis proteins have been identified as frequent features in cancer patients. As a result hereof, survivin-directed immunotherapy was quickly moved to the clinic [23,24] and several survivin-based vaccination trials are currently ongoing at different institutes. However, whereas survivin has been given much attention as a T-cell target, the Bcl-2 family has as yet received somewhat less attention. Here, we summarize current knowledge of Bcl-2 family proteins as T-cell antigen and discuss future opportunities.

**BCL-2**

Bcl-2 is a pivotal regulator of apoptotic cell death, and it is overexpressed in many cancers [25]. Consequently, the Bcl-2 protein is an attractive target for drug design and Bcl-2 specific antisense oligonucleotides or small molecule Bcl-2 inhibitors have shown broad anti-cancer activities in pre-clinical models and are currently in clinical testing [26]. However, Bcl-2 is in addition the target of spontaneous T-cell reactivity in cancer patients [27]. Hence, analyses of the protein sequence for HLA-binding motifs and subsequent testing of blood of tumor patients revealed spontaneous T-cell reactivity against Bcl-2 in patients suffering from unrelated tumor types, i.e., melanoma, pancreatic and breast cancer, as well as AML and B-CLL. These spontaneously occurring immune responses comprised of cytotoxic effector cells. This notion could be confirmed by ex vivo analysis of Bcl-2 reactive T cells which were capable of killing HLA-matched tumor cells [27]. Moreover, CTL clones recognizing Bcl-2-derived epitopes efficiently killed cancer cells of different origin, e.g., colorectal cancer, breast cancer and melanoma cells [28].

Bcl-2 is implicated in cancer development, tumor progression and protection of cells from a wide range of cytotoxic insults, including cytokine deprivation, irradiation, and chemotherapeutic drugs [29]. However, although Bcl-2 is an anti-apoptotic protein a rather paradoxical role of Bcl-2 have been described, showing an association between high Bcl-2 expression and improved
survival in different cancers [30,31]. Bcl-2 expression and prognosis has been correlated for breast cancer patients even if treated with chemotherapy [32]. Likewise, Bcl-2 expression has been associated with improved prognosis even among patients at very high risk for distant relapse [33]. In melanoma, it has been described that Bcl-2 expression was significantly higher in the primary tumors as compared to metastatic lesions [31]. These findings were unexpected since over-expression of Bcl-2 in tumor cell results in enhanced resistance to apoptosis in vitro [12]. The biological basis for the association between high Bcl-2 expression and improved survival is unclear. An explanation may be that poorly differentiated tumors depend on other prosurvival pathways, and decreased Bcl-2 expression merely is a marker of aggressive tumor behaviour rather than mechanistically associated with aggressive biology [25]. However, it could in addition suggest a pivotal role of Bc-2 specific T cells in immunosurveillance of cancer. The loss of the Bcl-2 expression during progression from primary to metastatic melanoma in patients suggests an active immune selection of the respective melanoma clones by the tumor bearing host, e.g. via a specific immune response.

BCL-X(L)

The bel-x gene is transcribed into two mRNAs through alternative splicing. The anti-apoptotic protein Bcl-X(L) is produced from the long isoform, while pro-apoptotic Bcl-X(S) is derived from the short isoform mRNA [34]. The protein product of the larger Bcl-X(L) differs from Bcl-X(S) protein by an inserted region (amino acids 126-188). The anti-apoptotic protein Bcl-X(L) plays an important role in cancer as it has been directly linked to resistance to conventional forms of therapies and poor prognosis [13]. Increased expression of Bcl-X(L) has been reported in a variety of different malignancies including AML and multiple myeloma as well as solid cancers like bladder cancer, breast cancer, pancreatic cancer and melanoma [13]. The functional inhibition of Bcl-X(L) restores the apoptotic process and renders neoplastic cells sensitive to chemical and radiation therapies, whereas manipulation of cancer cell lines to express high levels of Bcl-X(L) results in a multi-drug resistance phenotype. Thus, the attractiveness of targeting Bcl-X(L) in vaccination is based on the fact that downregulation or loss of expression of this protein as some form of immune escape would impair sustained tumor growth. The combination of immunotherapy targeting Bcl-X(L) with conventional chemotherapy appears to be particularly appealing since expression of this protein is correlated with drug resistance [35,36]. It was demonstrated that breast cancer patients, melanoma patients and pancreatic cancer patients host spontaneous HLA-restricted T-cell responses specifically against Bcl-X(L)-derived peptides [37]. In contrast, no responses were detected against Bcl-X(L) epitopes in healthy controls. Furthermore, Bcl-X(L) specific T cells not only killed target cells pulsed with the antigenic peptide but also recognized tumor cells endogenously expressing the Bcl-X(L) protein in an antigen specific and HLA-restricted manner [38]. Thus, whereas HLA-matched cancer cell lines of different origin were very effectively lysed by the Bcl-X(L) specific T cells, there was no lysis of the HLA-mismatched breast cancer cells. The killing of tumor cells of different origin underlines the universal characteristics of Bcl-X(L) as a tumor antigen. Importantly, the Bcl-X(L)-specific T cells did not only lyse in vitro generated tumor cell lines, but in addition lysed ex vivo enriched AML cells demonstrating that killing is not restricted to long-term cell lines. Since T cells and B cells normally express Bcl-X(L) following activation, Bcl-X(L) can not be considered to be a cancer-specific protein and caution is required when targeting this protein in vaccination therapies. However, the Bcl-X(L)-specific T cells did not kill purified B and T cells, which suggest that although non-malignant, B cells and T cells express Bcl-X(L), they escape recognition from Bcl-X(L) specific T cells. Similar findings have been reported for another anti-apoptotic protein, survivin. Thus, although activated B and T cells express survivin, survivin-specific CTL did not recognize and kill such cells ex vivo [39].

MCL-1

The lower rates of relapse in allogeneic transplantation compared with autologous bone marrow transplantation, the striking clinical benefit of donor-lymphocyte infusions as well as the finding that human T cells can destroy chemotherapy-resistant cell lines from chronic myeloid leukemia and multiple myeloma, have prompted development of immunotherapeutic strategies against haematological cancers [40]. Among these approaches, active specific immunization or vaccination is emerging as a valuable tool to boost the adaptive immune system against malignant cells. Mcl-1 is an apoptosis-inhibiting member of the Bcl-2 family that is expressed in early monocyte differentiation. Elevated levels of Mcl-1 have been reported for a number of solid and hematopoietic cancers, e.g. CLL and in AML and ALL upon relapse [13,15,16]. In CLL patients, higher levels of Mcl-1 are strongly correlated with failure to achieve complete remission after single-agent therapy. In multiple myeloma Mcl-1 plays an important role in the survival of malignant cells [41].

Using the IFN-g ELISPOT we demonstrated that both hematopoetic and solid cancer patients host spontaneous T-cell responses against Mcl-1-derived peptides [42-44]. Thus, strong and frequent CTL responses against Mcl-1 were detected in CLL patients, melanoma patients, pancreatic cancer patients and breast cancer patients, whereas no responses could be detected in healthy individuals. Mcl-1 specific T-cell clones effectively lysed...
Cancers, inhibition of apoptosis is a general feature, and described in other cancers [47-49]. Thus, in most human reduced AI. Although regulators adoptive T-cell transfer [52]. Subsequently, it may also e.g. induced by chemotherapy, enhances the efficacy of chemotherapy in myeloma patients [51]. Notably, lympho-ablation, leave to the induction of clinically relevant immunity described to improve the severe immunodeficiency and modulation of apoptosis – with active immune function – was unheard of. However, recent data from the clinic suggests a synergistic effect of anti-cancer vaccines and chemotherapy. As an example hereof, the combination of immunotherapy targeting these antigens with conventional chemotherapy appears to be particularly appealing. In a combinational therapeutic setting, conventional therapy would kill the majority of the cancer cells, leaving only cells that express high levels of antigens. Such high-expressers would be particularly vulnerable to killing by vaccination induced T cells. Thus, the synergy of these measures could potentially give a more effective treatment than the added effect of either regime alone; thereby strengthening the already described synergistic effect of anti-cancer vaccines and chemotherapy.

CONCLUSION

It has been have reported that spontaneous specific T-cell responses against the anti-apoptotic members of the Bcl-2 family are frequent in cancer patients and that these T cells are highly cytotoxic against cancer cells. Hence, Bcl-2 antigens appear to be a very attractive target for anti-cancer immunotherapy both in hematopoietic and
solid cancers. To evaluate the efficacy and safety of Bcl-2 family-based vaccinations the first phase I vaccination study have been started (from June 2010) at Herlev University Hospital, Denmark and Odense University Hospital, Denmark in which multiple myeloma patients are being vaccinated with HLA-restricted Bcl-2, Bcl-X(L) and/or Mcl-1-derived epitopes in connection with Montanide adjuvant (www.clinicaltrials.gov).

ACKNOWLEDGMENTS

This work was supported by grants from the The Novo Nordisk Foundation, The Danish Cancer Society, Danish Medical Research Council, The Lundbeck Foundation, The John and Birthe Meyer Foundation, The Juchum Foundation and Herlev University Hospital.

CONFLICT OF INTEREST

The authors declare no conflict of interest

REFERENCE LIST

1. Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. Hematology Am Soc Hematol Educ Program 2004;337-353.
2. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000; 182:323-331.
3. Larsen SK, Svane IM, thor Straten P, Andersen MH. Therapeutic Cancer Vaccines. Current Cancer Therapy Reviews 2010; 6:163-174.
4. Stevanovic S. Antigen processing is predictable: From genes to T cell epitopes. Transpl Immunol 2005; 14:171-174.
5. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54:187-207.
6. Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 2008; 90:173-180.
7. Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13:539-545.
8. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewska S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60:23-32.
9. Hua C, Raffeld M, Ko HS, Fast P, Bakhshi A, Cossman J. Mechanism of bcl-2 activation in human follicular lymphoma. Oncogene 1990; 5:233-235.
10. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 2003; 4:211-218.
11. Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci U S A 1996; 93:7063-7068.
12. Coults L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003; 13:115-123.
13. Shangary S, Johnson DE. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003; 17:1470-1481.
14. Krajewska M, Krajewski S, Epstein II, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148:1567-1576.
15. Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG, Adamson E, Reed JC. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 1998; 47:129-140.
16. Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G, Zhou X, Ho VC, Trotter MJ. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4:1865-1871.
17. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009; 9:320-340.
18. Kim R, E Mi M, Matsuura K, Tanabe K. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 2007; 14:1-11.
19. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 30:133-142.
20. Li J, Viallet J, Haura EB. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol 2008; 61:525-534.
21. Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010; %20.
22. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24:4738-4745.
23. Otto K, Andersen MH, Eggert AO, Keikavoussi P, Pedersen LO, Rath JC, Bock M, Brocker EB, thor Straten P, Kampgen E, Becker JC. Therapy-induced T cell responses against the universal tumor antigen survivin. Vaccine 2004; 23:884-889.

24. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55:1294-1298.

25. Nadler Y, Camp RL, Giltmane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008; 10:R35.

26. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol 2009; 21:516-523.

27. Andersen MH, Svane IM, Kivistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, Thor SP. Immunogenicity of Bcl-2 in cancer patients. Blood 2005; 15:728-734.

28. Sorensen RB, Junker N, Kirk A, Voigt H, Svane IM, Becker JC, Thor SP, Andersen MH. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines. Cancer Immunol Immunother 2009; 58:665-675.

29. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22:8590-8607.

30. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12:2468-2475.

31. Divito KA, Berger AJ, Camp RL, Dobbled-Filhart M, Rimm DL, Kluger HM. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 2004; 64:8773-8777.

32. Blagosklonny MV. Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? Bioessays 2001; 23:947-953.

33. Kroger N, Milde-Langosch K, Riethdorf S, Schmooer C, Schumacher M, Zander AR, Loning T. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006; 12:159-168.

34. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.

35. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071-5074.

36. Nakagawara A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 1998; 11:115-124.

37. Andersen MH, Reker S, Kivistborg P, Becker JC, thor Straten P. Spontaneous immunity against Bcl-X(L) in cancer patients. J Immunol 2005; 175:2709-2714.

38. Sorensen RB, Hadrup SR, Kollgaard T, Svane IM, Thor SP, Andersen MH. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother 2007; 56:527-533.

39. Schmidt SM, Schag K, Muller MR, Week MM, Appel S, Kanz L, Grunebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102:571-576.

40. Mocellin S, Semenzato G, Mandruzzato S, Riccardo RC. Part II: Vaccines for haematological malignant disorders. Lancet Oncol 2004; 5:727-737.

41. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99:1885-1893.

42. Andersen MH, Becker JC, thor Straten P. The anti-apoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients. Leukemia 2005; 19:484-485.

43. Andersen MH, Kivistborg P, Becker JC, thor Straten P. Identification of an HLA-A1 restricted CTL epitope from Mcl-1. Leukemia 2005; 19:1084-1085.

44. Andersen RS, Wenandy L, Sorensen RB, Thor SP, Andersen MH. Mcl-1 and anticancer vaccination: identification of an HLA-A2 restricted epitope. Leukemia 2008; 22:668-669.

45. Sorensen RB, Nielsen OJ, Thor SP, Andersen MH. Functional capacity of Mcl-1-specific cytotoxic T-cells. Leukemia 2006; 20:1457-1458.

46. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6:127-134.

47. Harada N, Hata H, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Kimura T, Matsuzaki H, Mitsuha Y. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6:127-134.

48. Varin E, Denoyelle C, Brodin E, Meryet-Figuiere M, Giffard R, Abeilard E, Goux D, Gauduchon P, Icard P, Poullain L. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 2010; 31:984-993.

49. Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, Schormann W, Selinski S, Freis E, Schwender H, Brulport M, Ickstadt K, Rahnenfuehrer J, Maccoux L, West J, Kolb H, Schuler M, Hengstler JG. ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. Clin Cancer Res 2010; 16:451-460.
50. Andersen MH, Sorensen RB, Schrama D, Svane IM, Becker JC, Thor SP. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 2008; 57:1735-1743.

51. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Research 2005; 65:8059-8064.

52. Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Semin Oncol 2007; 34:524-531.

53. Sakaguchi S. Regulatory T cells. Springer Semin Immunopathol 2006; 28:1-2.

54. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052-3061.

55. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabriovich DI. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120:1111-1124.

56. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61.

57. Makin G, Hickman JA. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000; 301:143-152.

58. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205:275-292.